DVAX Dynavax Pharma Operating Sales Margin

Symbol and logo of brand Dynavax Technologies Corp (DVAX)

Steady demand for Heplisav-B, driven by high efficacy, strengthens the position of Dynavax Technologies (DVAX). The operating margin clearly demonstrates current profitability, where 3.20 shows the value of this parameter. Returns are based on vaccine sales and royalties from CpG 1018. Additional growth is provided by partnerships to create immune preparations for global pharma behemoths.

DVAX: Dynavax Technologies Corporation Operating Margin 07/04/2022 - 02/21/2026

dynavax.com - analytical breakdowns and key metrics (DVAX)

- share price and consensus valuation forecast:
Fundamental valuation:Dynavax Pharma, DVAX
Brand item of Dynavax Technologies

Operating margin reflects the share of profit from core operations in total revenue before taxes and interest. Analyzing the average operating margin allows for an assessment of the efficiency of internal cost management. The metric is calculated by dividing operating profit by net income. For Dynavax Technologies (DVAX), the implementation of sustainable packaging standards and the modernization of production lines directly impact the structure of these costs. Resource optimization confirms the resilience of the business model.